Mike Crichton, Senior Vice President of GlaxoSmithKline (GSK, NYSE: GSK) for the Greater China and Intercontinental Region (GSK GCI), has announced significant personnel changes within the organization. Cecilia Qi, currently the Global Vice President of GSK and General Manager (GM) of China, has been promoted to Vice President and Head of GSK’s vaccine business for the GSK Greater China and Intercontinental Region. She will be succeeded by Sherman Yu.
Since taking the reins as GSK China’s General Manager in January 2020, Cecilia Qi has overseen the launch of 21 new products and indications. Notable launches include the zoster vaccine Shingrix, Nucala (mepolizumab) for severe eosinophilic asthma, and Benlysta (belimumab) for systemic lupus erythematosus. Sherman Yu, who became the Greater China President of Sandoz, a division of Novartis focused on generic drugs, in 2022, will step into the role of GSK’s Vice President and General Manager for Taiwan.
The official transition will occur on June 1, with both leaders assuming their new roles starting July 1, 2024.- Flcube.com
